CAJ | 학술논문

非小细胞肺癌（ NSCLC）是最常见的恶性肿瘤之一，也是导致癌症死亡的主要原因，其疗效欠佳、预后差，尤其是伴有脑转移患者。 NSCLC伴脑转移患者生活质量差，预后不良，自然中位生存期仅为1～2个月，全脑放射治疗虽然在一定程度上改善了患者的生活质量，延长了患者的生存期，但疗效仍不理想。近年来围绕培美曲塞、替莫唑胺以及表皮生长因子受体酪氨酸激酶抑制剂（ EGFR-TKIs）开展了一些研究，并取得了一定的成果。本文就针对培美曲塞、替莫唑胺及EGFR-TKIs等抗肿瘤药物在NSCLC伴脑转移中的研究进展进行综述。
비소세포폐암（ NSCLC）시최상견적악성종류지일，야시도치암증사망적주요원인，기료효흠가、예후차，우기시반유뇌전이환자。 NSCLC반뇌전이환자생활질량차，예후불량，자연중위생존기부위1～2개월，전뇌방사치료수연재일정정도상개선료환자적생활질량，연장료환자적생존기，단료효잉불이상。근년래위요배미곡새、체막서알이급표피생장인자수체락안산격매억제제（ EGFR-TKIs）개전료일사연구，병취득료일정적성과。본문취침대배미곡새、체막서알급EGFR-TKIs등항종류약물재NSCLC반뇌전이중적연구진전진행종술。
Non-small cell lung cancer( NSCLC) is one of the most common malignant tumor and a major cause of death from cancer. NSCLC patients often poorly responds to chemotherapy and has a relatively poor prognosis, especially in those patients with brain metastases. NSCLC patients with brain metastases have poor prognosis and worse quality of life;the natural median survival time is only 1-2 months. To some extent,whole brain radiation therapy improves quality of life and prolongs the survival time in NSCLC pa-tients with brain metastases;but the curative effects are still unsatisfactory.In recent years,some research around pemetrexed,temozolo-mide and epidermal growth factor receptor-tyrosine kinase inhibitors( EGFR-TKIs) are conducted and achieves certain results. In this paper,we review the progress of drugs in NSCLC with brain metastasis.